Ixico Regulatory News (IXI)

14 June 2022

IXICO plc

("IXICO" or the "Company")

Contract Extension in Huntington's disease worth circa £0.8 million

IXICO plc (AIM: IXI), the neuroimaging Contract Research Organisation (CRO) delivering advanced AI analytical insights in neuroscience, is pleased to announce that an existing client has asked IXICO to extend its breadth of services to them on their phase I/II trial into HD, which was originally announced in April 2019. This results in a contract extension worth circa £0.8m which IXICO expects to deliver across a period of 4 years.

HD is a rare, inherited disease that causes the progressive breakdown of nerve cells in the brain affecting movement, mood and thinking abilities.

For further information please contact:

About IXICO | Advanced Analytics | Intelligent Insights.

IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's, Parkinson's, Alzheimer's disease and Multiple Sclerosis. The Company's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience by supporting pharmaceutical companies across all phases of CNS clinical research. IXICO's goal is to be a leading advocate of artificial intelligence in medical image analysis.

IXICO has developed and deployed breakthrough machine learning Ai data analytics, at scale, through its remote access TrialTracker technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the Company's pharmaceutical clients.

More information is available on www.IXICO.com and follow us on Twitter @IXICOnews